There is still no strategy to directly overcome Merlin deficiency in Neurofibromatosis type 2 and cancers; therefore, targeting the collateral effect of loss of Merlin function seems like a promising approach. The gene discussed is NF2; the disease is NF2-related schwannomatosis.